CCP
ABCL icon

Clough Capital Partners’s AbCellera Biologics ABCL Stock Holding History

Clough Capital Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-971,297
Closed -$19.5M – 112
2021
Q3 		$19.5M Buy
971,297
+272,497
+39% +$4.82M 1.18% 33
2021
Q2 		$15.4M Buy
698,800
+224,316
+47% +$6.19M 0.84% 52
2021
Q1 		$16.1M Buy
+474,484
New +$18.9M 0.72% 54

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Clough Capital Partners's ABCL Position: Q4 2021 in Review

Clough Capital Partners sold out of AbCellera Biologics (ABCL) in Q4 2021, closing a stake of 971,297 shares — an estimated $19.5M sold.

Clough Capital Partners first reported a position in ABCL in Q1 2021 and held it in 3 quarters. The position peaked at $19.5M in Q3 2021. 124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

  • Clough Capital Partners reported no remaining AbCellera Biologics position as of Q4 2021 after selling out during the quarter.
  • Clough Capital Partners sold 971,297 AbCellera Biologics shares in Q4 2021, an estimated $19.5M.
  • Clough Capital Partners first reported a position in AbCellera Biologics in Q1 2021 and held it in 3 quarters.
  • Clough Capital Partners's AbCellera Biologics position peaked at $19.5M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on Clough Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.